109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
内镜逆行胰胆管造影术在高龄人群中的疗效及安全性
Authors He JL, Zhu L, Yang ZZ, Hong JB , Xing YW, Zhang SY, Wang YH, Wang YW, Zhou XD, Zhou XJ, Li GH, Zhu Y, Chen YX
Received 18 May 2025
Accepted for publication 14 October 2025
Published 1 November 2025 Volume 2025:20 Pages 1835—1846
DOI https://doi.org/10.2147/CIA.S541278
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Maddalena Illario
Jin-Li He, Liang Zhu, Zhen-Zhen Yang, Jun-Bo Hong, Ya-Wei Xing, Shi-Yu Zhang, You-Hua Wang, Yun-Wu Wang, Xiao-Dong Zhou, Xiao-Jiang Zhou, Guo-Hua Li, Yin Zhu, You-Xiang Chen
Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China
Correspondence: Liang Zhu, Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwaizheng Street, Nanchang, 330006, People’s Republic of China, Tel +86-791-88694228, Email 89493075@qq.com
Background: There are presently limited clinical studies of endoscopic retrograde cholangiopancreatography (ERCP) in the longevous (elders aged no less than 90 years old). This study aimed to evaluate the efficacy and safety of ERCP in longevous patients.
Methods: A total of 113 longevous patients who underwent ERCP for the first time at our center from January 8th, 2009 to December 20th, 2023 were enrolled. Correspondingly, the control groups included the old-old (75– 89 years) patient group and the young-old (60– 74 years) patient group. Each of the control group was matched in a 1:2 ratio to the longevous patient group based on the gender, presence of choledocholithiasis, endoscopic sphincterotomy, endoscopic papillary balloon dilatation, periampullary diverticulum, the placement of biliary stent, and guidewire entry into the pancreatic ducts, ultimately including 226 patients in each control group. Baseline characteristics, clinical and endoscopic data were compared among the three groups, and risk factors for post-ERCP pancreatitis in elderly patients were analyzed.
Results: Except for the higher incidence of acute cholangitis and atrial fibrillation (AF) in longevous patients, the three elderly patient groups were comparable in baseline characteristics. The technical success rate of ERCP in longevous patients was 95.6%, which has no significant difference from that of old-old patients (95.1%) and young-old patients (96.9%) during the same period. The overall incidence of post-ERCP adverse events was 12.9%, and there was no significant difference in the incidence and mortality of adverse events among the three groups. PEP was the most common adverse event after ERCP in elderly patients. Multivariable logistic regression analysis showed endoscopic metal biliary endoprothesis (OR=2.351, 95% CI 1.144– 4.832, P=0.020), pancreatic duct opacification (OR=5.774, 95% CI 1.062– 31.383, P=0.042) were independent risk factors for PEP in elderly patients.
Conclusion: ERCP is safe and effective in the longevous population, and advanced age did not increase the incidence of adverse events after ERCP.
Keywords: the longevous, endoscopic retrograde cholangiopancreatography, efficacy, safety, risk factors
Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People’s Republic of China
Correspondence: Liang Zhu, Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Center for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwaizheng Street, Nanchang, 330006, People’s Republic of China, Tel +86-791-88694228, Email 89493075@qq.com
Background: There are presently limited clinical studies of endoscopic retrograde cholangiopancreatography (ERCP) in the longevous (elders aged no less than 90 years old). This study aimed to evaluate the efficacy and safety of ERCP in longevous patients.
Methods: A total of 113 longevous patients who underwent ERCP for the first time at our center from January 8th, 2009 to December 20th, 2023 were enrolled. Correspondingly, the control groups included the old-old (75– 89 years) patient group and the young-old (60– 74 years) patient group. Each of the control group was matched in a 1:2 ratio to the longevous patient group based on the gender, presence of choledocholithiasis, endoscopic sphincterotomy, endoscopic papillary balloon dilatation, periampullary diverticulum, the placement of biliary stent, and guidewire entry into the pancreatic ducts, ultimately including 226 patients in each control group. Baseline characteristics, clinical and endoscopic data were compared among the three groups, and risk factors for post-ERCP pancreatitis in elderly patients were analyzed.
Results: Except for the higher incidence of acute cholangitis and atrial fibrillation (AF) in longevous patients, the three elderly patient groups were comparable in baseline characteristics. The technical success rate of ERCP in longevous patients was 95.6%, which has no significant difference from that of old-old patients (95.1%) and young-old patients (96.9%) during the same period. The overall incidence of post-ERCP adverse events was 12.9%, and there was no significant difference in the incidence and mortality of adverse events among the three groups. PEP was the most common adverse event after ERCP in elderly patients. Multivariable logistic regression analysis showed endoscopic metal biliary endoprothesis (OR=2.351, 95% CI 1.144– 4.832, P=0.020), pancreatic duct opacification (OR=5.774, 95% CI 1.062– 31.383, P=0.042) were independent risk factors for PEP in elderly patients.
Conclusion: ERCP is safe and effective in the longevous population, and advanced age did not increase the incidence of adverse events after ERCP.
Keywords: the longevous, endoscopic retrograde cholangiopancreatography, efficacy, safety, risk factors